Micronoma in the News

Forbes has named Micronoma CAO and Co-founder Gregory Sepich-Poore one of its 30 Under 30 in Healthcare for 2023.  Read more at Forbes.  

A flurry of microbiome research over the past two decades has led to many insights about the link between the microbes and health, but now the race to the clinic is on. Over the past two decades scientists have been working steadily to unravel the complex interplay of...

Experts say fungi can be found in a variety of places in the human body as well as in cancer tumors. Researchers say the microorganisms may be useful in developing new diagnostic tools and treatments. They say fungi may be able to develop biomarkers to detect cancer...

An international team of scientists, co-led by researchers at the University of California San Diego School of Medicine, has created the first pan-cancer mycobiome atlas — a survey of 35 types of cancer and their associated fungi. The findings are published September...

Fungal DNA is present in various types of cancer, according to two studies published yesterday (September 29) in Cell. The findings add support to a hypothesized link between fungi and certain cancers, although researchers emphasize that there isn’t yet evidence for a...

A research team led by the University of California San Diego and the Weizmann Institute of Science in Israel has created an atlas of fungi linked to a range of 35 different cancers for the first time. As reported in the journal Cell, the researchers hope the new...

By Deborah Borfitz  September 22, 2022 | Emerging approaches to the early detection of cancer, based on metabolic profiling and microbiome- and exosome-driven liquid biopsies, were highlighted during the recent Next Generation Dx Summit held in Washington, D.C....

When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...

The health category of Fast Company’s World Changing Ideas Awards honors medical innovations that save lives, extend longevity, or increase access to care. See the finalists and honorable mentions below, and read about the winner, the pill that could make routine...

As a postdoc at the Broad Institute of MIT and Harvard in 2008, cancer biologist Ravid Straussman worked on a collaborative effort to screen normal cells for their influence on cancer cells’ responses to various anticancer therapies. The project turned up hundreds of...

With its Oncobiota platform, Micronoma is pioneering the analysis of the cancer microbiome for early cancer detection and creating tools for personalized cancer treatment. Read More

Interview with Sandrine Miller-Montgomery, Micronoma, Inc. What are your suggestions to encourage more young women to pursue careers in tech? There are so many facets to working in tech that it is worth considering regardless of being scientific minded or not...the...

After controlling for high levels of bacterial contamination in their lab and reagents, researchers detect microbial genetic material in plasma samples from healthy people and cancer patients. Read the full article in The Scientist

Micronoma, a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round. Read full story.

Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine. Read how Micronoma fits in this emerging landscape. Read Article

Read the full article on GenomeWeb.

San Diego-based Micronoma, a startup using microbiome analysis for early cancer detection, has appointed Magda Marquet as chairman of the firm’s board.

Microbiomics is taking a sharp turn. Until now, the field was limited to fecal transplants from healthy patients to those with gut conditions. The transplant is an awkward procedure that also creates regulatory and other challenges. Read More.

Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. Read More.

San Diego-based Micronoma closed $3 million in seed financing to support the development of its microbiome-based cancer detection technology. Full Article

13 Aug. 2020. A new company, spun off from university biomedical engineering labs, is creating early cancer diagnostics by analyzing microbial genetics in simple blood samples. Micronoma, in San Diego, is also raising $3 million in its seed funding round, equity...